de Millas Walter, Lambert Martin, Naber Dieter
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dialogues Clin Neurosci. 2006;8(1):131-6. doi: 10.31887/DCNS.2006.8.1/wmillas.
The patients' perspective of antipsychotic treatment was largely neglected for a long period. It has only been during the last 10 years, with the development of atypical antipsychotics, that scientific interest in this issue has markedly increased. Numerous studies have shown that the majority of schizophrenic patients are able to fill out a self-rating scale in a meaningful way, and several self-report scales with sufficient internal consistency and good construct validity have been developed. The effects of antipsychotic treatment on psychopathology and on subjective well-being (SW) are not strongly related; the perspectives of the patient and his/her psychiatrist markedly differ. Recent research indicates that SW/quality of life, much more improved by atypical than by typical antipsychotics, has a strong impact on compliance, as well as on the chance of achieving remission. The data strongly suggest that a systematic evaluation of the patient's perspective of antipsychotic treatment is meaningful and necessary to increase compliance, functional outcome, and long-term prognosis.
长期以来，患者对抗精神病药物治疗的看法在很大程度上被忽视了。直到最近10年，随着非典型抗精神病药物的发展，科学界对这个问题的兴趣才显著增加。大量研究表明，大多数精神分裂症患者能够以有意义的方式填写自评量表，并且已经开发出了几种具有足够内部一致性和良好结构效度的自我报告量表。抗精神病药物治疗对精神病理学和主观幸福感（SW）的影响并没有很强的相关性；患者及其精神科医生的观点明显不同。最近的研究表明，非典型抗精神病药物比典型抗精神病药物更能改善SW/生活质量，这对依从性以及实现缓解的机会有很大影响。数据强烈表明，系统评估患者对抗精神病药物治疗的看法对于提高依从性、功能结局和长期预后是有意义且必要的。
